Overview
BIIB market data
Price History
BIIB price chart
Valuation & Profitability
- P/E (TTM)
- 21.84 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $8.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $124.56 – $219.72 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $30K · P/B 1.41 · P/S 3.02.
Company news
Guggenheim Maintains Buy on Biogen, Raises Price Target to $280Benzinga · Jul 21, 2026, 1:48 PM
B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215Benzinga · Jul 21, 2026, 12:34 PM
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS InsiderGlobenewswire Inc · Jul 15, 2026, 3:15 PM
Why Is Biogen Stock Falling Tuesday?Benzinga · Jul 14, 2026, 3:49 PM
Eisai And Biogen Present Real‑World LEADER Study Data At AAIC Showing Nearly 83% Of Early Alzheimer’s Patients Remained Stable Or Improved On LEQEMBI Therapy Over ~17 Months, With Consistent Results Across Diverse Groups.Benzinga · Jul 14, 2026, 3:28 PM
Biogen shares are trading lower. The company presented Phase 2 CELIA data at AAIC showing meaningful clinical outcomes and robust tau reduction with investigational Alzheimer’s therapy diranersen, with plans to advance into Phase 3.Benzinga · Jul 14, 2026, 2:22 PM
Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of BoxesBenzinga · Jul 14, 2026, 1:17 PM
Eisai Co And Biogen Receive FDA's Approval For A Supplemental Biologics License Application For A Once-Weekly Lecanemab-Irmb Subcutaneous Injection As An Initiation Dose For The Treatment Of Early Alzheimer’s Disease; U.S. Launch Of LEQEMBI IQLIK As An Initiation Dose Planned For Late August 2026Benzinga · Jul 13, 2026, 9:42 PM
FDA Grants Approval For At-Home Starting Dose For Alzheimer's Treatment LeqembiBenzinga · Jul 13, 2026, 6:23 PM
Biogen shares are trading higher after Truist Securities upgraded the stock from Hold to Buy rating and raised its price target from $190 to $235.Benzinga · Jul 13, 2026, 6:20 PM